reported that invasive and metastatic breast cancer cells can be differentiated into adipocytes by MEK inhibitors and rosiglitazone, and invasion and metastasis abilities were inhibited in breast cancer (Tables 3 and 4). This evidence concerns the gene MAP2K7 and breast carcinoma.